These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 5453572)

  • 1. [Medroxyprogesterone and endometrial adenocarcinoma].
    Serment H; Spitalier JM; Ayme Y; Degiovanni E; Bardin JP
    Bull Fed Soc Gynecol Obstet Lang Fr; 1970; 22(1):93-7. PubMed ID: 5453572
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study.
    Cohen CJ; Deppe G; Bruckner HW
    Obstet Gynecol; 1977 Oct; 50(4):415-7. PubMed ID: 904803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of medroxyprogesterone (MAP) therapy on the DNA content in adenocarcinoma of the human endometrium].
    Vecchietti G; Gerzeli G; Zanoio L; Novelli GG; Barni S
    Minerva Ginecol; 1979; 31(7-8):597-603. PubMed ID: 481819
    [No Abstract]   [Full Text] [Related]  

  • 4. Progestins in the treatment of endometrial carcinoma.
    Anderson DG
    Surg Forum; 1965; 16():398-400. PubMed ID: 5835208
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of adenocarcinoma of the endometrium with synthetic progestogens].
    Lanza A; Fedele M; Renzetti ME; Ferraris G
    Minerva Ginecol; 1981 Oct; 33(10):917-36. PubMed ID: 7031519
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of treatment with oral 6-methyl-17-hydroxyprogesterone acetate in endometrial adenocarcinoma. Histochemical and ultrastructural aspects].
    Vecchietti G; Gerzeli G; Zanoio L; Novelli GG; Barni S; Patton R
    Minerva Ginecol; 1981 Apr; 33(4):293-306. PubMed ID: 7243070
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytologic evaluation of exclusive medroxyprogesterone acetate treatment for vaginal recurrence of endometrial adenocarcinoma.
    Bonte J; Drochmans A; Ide P
    Acta Cytol; 1970 May; 14(5):353-6. PubMed ID: 5284269
    [No Abstract]   [Full Text] [Related]  

  • 8. [MAP in the therapy of adenocarcionoma of the endometrium. Immediate clinical results and general endocrine effects].
    Ricciardi I; Calì A; Imparato E; Marino L; Pesando P
    Minerva Ginecol; 1975 Sep; 27(9):744-53. PubMed ID: 1207966
    [No Abstract]   [Full Text] [Related]  

  • 9. [New technic of pre-surgical medical treatment of adenocarcinoma of the endometrium].
    Martella E; Torella M; Messalli EM; Quirino R
    Arch Ostet Ginecol; 1978; 83(3-4):81-91. PubMed ID: 757771
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment of uterine adenocarcinoma with medroxyprogesterone acetate.
    Horger EO; Williamson HO; Hester LL
    J S C Med Assoc; 1966 Jun; 62(6):217-23. PubMed ID: 5227728
    [No Abstract]   [Full Text] [Related]  

  • 11. [MAP in the treatment of adenocarcinoma of the endometrium].
    Leone F; De Placido G; Frollo G
    Minerva Ginecol; 1979 Apr; 31(4):251-5. PubMed ID: 460664
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of the mechanism of action of a progestin on endometrial andenocarcinoma.
    Anderson DG
    Surg Forum; 1969; 20():411-3. PubMed ID: 5376941
    [No Abstract]   [Full Text] [Related]  

  • 13. [Action of MAP in adenocarcinoma of the endometrium. Clinical results and ultrastructural and histochemical study].
    Pullè C; Rigano A
    Minerva Ginecol; 1981 Oct; 33(10):937-54. PubMed ID: 7031520
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of adenocarcinomas of the uterine body with medroxyprogesterone].
    Bonte J; Drochmans A; Lassance M
    Gynecol Obstet (Paris); 1966; 65(2):179-85. PubMed ID: 5942790
    [No Abstract]   [Full Text] [Related]  

  • 15. [Flow cytometric study on the action of progestogen in patients with adenocarcinoma and precancerous lesions of the endometrium].
    Nishiya I; Izutsu T; Satoh K; Yoshizumi N; Kurokawa Y; Kagabu T
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jul; 37(7):1161-8. PubMed ID: 3161958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaginal cytologic evaluation as a practical link between hormone blood levels and tumor hormone dependency in exclusive medroxyprogesterone treatment of recurrent or metastatic endometrial adenocarcinoma.
    Bonte J; Decoster JM; Ide P
    Acta Cytol; 1977; 21(2):218-24. PubMed ID: 266331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progestins in combined treatment of endometrial cancer].
    Voznyĭ EK; Titova VA
    Sov Med; 1990; (9):102-7. PubMed ID: 2148437
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical and histological studies of endometrial carcinoma of the uterus treated with medroxy-progesterone-acetate (author's transl)].
    Ohta M; Takeda A; Ninagawa T; Tomoda Y
    Nihon Gan Chiryo Gakkai Shi; 1980 Dec; 15(7):1098-103. PubMed ID: 6453176
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
    Kline RC; Freedman RS; Jones LA; Atkinson EN
    Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831
    [No Abstract]   [Full Text] [Related]  

  • 20. Hormonal treatment of recurrent endometrial carcinoma. Report of a case.
    Nilsen PA
    J Obstet Gynaecol Br Commonw; 1968 Jan; 75(1):99-100. PubMed ID: 5635249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.